Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca’s Tagrisso has been approved in the EU for treating adult patients with unresectable EGFR-mutated non-small cell lung cancer (NSCLC), marking a significant breakthrough as the first and only EGFR inhibitor for this condition in the region. The approval, based on the LAURA Phase III trial results, shows Tagrisso significantly extends progression-free survival, setting a new standard of care for these patients and reinforcing the importance of timely EGFR mutation testing.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
YTD Price Performance: -1.12%
Average Trading Volume: 2,667,942
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £159B
Learn more about AZN stock on TipRanks’ Stock Analysis page.
